蛋白激酶B
癌症研究
肝细胞生长因子
PI3K/AKT/mTOR通路
拼接因子
MAPK/ERK通路
生物
SR蛋白
RNA剪接
选择性拼接
细胞生物学
激酶
信号转导
遗传学
信使核糖核酸
核糖核酸
基因
受体
作者
Úrsula Muñoz,Juan Enrique Puche,Rebekka A. Hannivoort,Ursula E. Lang,Michal Cohen‐Naftaly,Scott L. Friedman
标识
DOI:10.1158/1541-7786.mcr-12-0213
摘要
Abstract Alternative splicing of the Krüppel-like factor 6 (KLF6) tumor suppressor into an antagonistic splice variant 1 (SV1) is a pathogenic event in several cancers including hepatocellular carcinoma (HCC) because elevated SV1 is associated with increased tumor metastasis and mortality. Ras activation is one factor that can enhance KLF6 splicing in cancer cells, however pathways driving KLF6 splicing are unknown. Splice site selection is regulated by splice factors that include serine/arginine-rich (SR) proteins such as SRSF1 (ASF-SF2), which in turn is controlled by phosphoinositide 3-kinase (PI3K)/Akt and the mitogen-activated protein kinase (MAPK) signaling pathway. Because signaling pathways downstream of the liver mitogen hepatocyte growth factor (HGF) include Akt, we explored whether HGF induces KLF6 alternative splicing. In HepG2 cells, HGF (25 ng/mL) significantly increases the ratio of SV1/KLF6 full by 40% through phosphorylation of Akt and subsequent downregulation of two splicing regulators, SRSF3 (SRp20) and SRSF1. Decreased SRSF3 levels regulate SRSF1 levels by alternative splicing associated with the nonsense-mediated mRNA decay pathway (AS-NMD), which stimulates cell growth by decreasing p21 levels. Enhanced cell replication through increased KLF6 alternative splicing is a novel growth-promoting pathway of HGF that could contribute to the molecule's mitogenic activity in physiologic liver growth and hepatocellular carcinoma. Mol Cancer Res; 10(9); 1216–27. ©2012 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI